

Suspend the Rules and Pass the Bill, H.R. 5353, With an Amendment

(The amendment strikes all after the enacting clause and inserts a new text)

115TH CONGRESS
2^D SESSION

H. R. 5353

To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

IN THE HOUSE OF REPRESENTATIVES

MARCH 20, 2018

Mr. LANCE (for himself, Mr. KENNEDY, Mr. COLLINS of New York, Ms. ESHOO, Mr. BARTON, and Ms. MATSUI) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to reauthorize and expand a program of surveillance and education, carried out by the Centers for Disease Control and Prevention, regarding infections associated with injection drug use.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Eliminating Opioid Re-
5 lated Infectious Diseases Act of 2018”.

1 **SEC. 2. REAUTHORIZATION AND EXPANSION OF PROGRAM**
2 **OF SURVEILLANCE AND EDUCATION RE-**
3 **GARDING INFECTIONS ASSOCIATED WITH IL-**
4 **LICIT DRUG USE AND OTHER RISK FACTORS.**

5 Section 317N of the Public Health Service Act (42
6 U.S.C. 247b–15) is amended to read as follows:

7 **“SEC. 317N. SURVEILLANCE AND EDUCATION REGARDING**
8 **INFECTIONS ASSOCIATED WITH ILLICIT**
9 **DRUG USE AND OTHER RISK FACTORS.**

10 “(a) IN GENERAL.—The Secretary may (directly and
11 through grants to public and nonprofit private entities)
12 provide for programs for the following:

13 “(1) To cooperate with the States and Indian
14 tribes in implementing or maintaining a surveillance
15 system to determine the incidence of infections com-
16 monly associated with illicit drug use, including in-
17 fections commonly associated with injection drug use
18 such as viral hepatitis, human immunodeficiency
19 virus, and infective endocarditis, and to assist the
20 States in determining the prevalence of such infec-
21 tions, which may include the reporting of cases of
22 such infections.

23 “(2) To identify, counsel, and offer testing to
24 individuals who are at risk of infections as a result
25 of injection drug use, receiving blood transfusions
26 prior to July 1992, or other risk factors.

1 “(3) To provide appropriate referrals for coun-
2 seling, testing, and medical treatment of individuals
3 identified under paragraph (2) and to ensure, to the
4 extent practicable, the provision of appropriate fol-
5 low-up services.

6 “(4) To develop and disseminate public infor-
7 mation and education programs for the detection
8 and control of infections described in paragraph (1),
9 with priority given to high-risk populations as deter-
10 mined by the Secretary.

11 “(5) To improve the education, training, and
12 skills of health professionals in the detection and
13 control of infections and the coordination of treat-
14 ment of addiction and infectious diseases described
15 in paragraph (1), with priority given to substance
16 use disorder treatment providers, pediatricians and
17 other primary care providers, obstetrician-gyne-
18 cologists, infectious diseases clinicians, and HIV cli-
19 nicians.

20 “(b) LABORATORY PROCEDURES.—The Secretary
21 may (directly or through grants to public and nonprofit
22 private entities) carry out programs to provide for im-
23 provements in the quality of clinical-laboratory procedures
24 regarding infections described in subsection (a)(1).

25 “(c) DEFINITIONS.—In this section:

1 “(1) The term ‘Indian tribe’ has the meaning
2 given that term in section 4 of the Indian Self-De-
3 termination and Education Assistance Act.

4 “(2) The term ‘injection drug use’ means—

5 “(A) intravenous administration of a sub-
6 stance in schedule I under section 202 of the
7 Controlled Substances Act;

8 “(B) intravenous administration of a sub-
9 stance in schedule II, III, IV, or V under sec-
10 tion 202 of the Controlled Substances Act that
11 has not been approved for intravenous use
12 under—

13 “(i) section 505 of the Federal Food,
14 Drug and Cosmetic Act; or

15 “(ii) section 351 of the Public Health
16 Service Act; or

17 “(C) intravenous administration of a sub-
18 stance in schedule II, III, IV, or V under sec-
19 tion 202 of the Controlled Substances Act that
20 has not been prescribed to the person using the
21 substance.

22 “(d) AUTHORIZATION OF APPROPRIATIONS.—For the
23 purpose of carrying out this section, there are authorized
24 to be appropriated \$40,000,000 for each of the fiscal years
25 2019 through 2023.”.